Syndax Pharmaceuticals Inc. [SNDX] has traded in a range of $6.32 to $24.89 in the last 1 year. As of this writing, the stock is at $24.80, up 0.94%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, SNDX shares are 7.43% up with the monthly amount drift of 24.41% and seems well in a long time frame.
On 6, December 2020, Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD. According to news published on Yahoo Finance, – Data featured during oral session at the 62nd ASH Annual Meeting demonstrate deep, durable responses and multiorgan clinical benefit in patients refractory to multiple therapeutic agents -.
Analyst Birdseye View:
The most recent analyst activity for Syndax Pharmaceuticals Inc. [NASDAQ:SNDX] stock was on May 22, 2020, when it was Upgrade with a Buy rating from Citigroup, which also lowered its 12-month price target on the stock from $26 to $23. Before that, on December 03, 2020, Stifel Recapitulated a Buy rating and elevated its amount target to $32. On May 22, 2020, H.C. Wainwright Downgrade a Neutral rating and plunged its price target on this stock from $25 to $15. On May 18, 2020, Citigroup Downgrade a Neutral rating. On May 11, 2020, H.C. Wainwright Reiterated a Buy rating and increased its price target to $25. On March 04, 2020, Barclays Initiated an Overweight rating and boosted its amount on this stock to $15. On January 13, 2020, H.C. Wainwright Reiterated a Buy rating and boosted its target amount on this stock from $15 to $17. On March 08, 2019 H.C. Wainwright Reiterated a Buy rating and elevated its amount target to $16.
In the past 52 weeks of trading, this stock has oscillated between a low of $6.32 and a peak of $24.89. Right now, the middling Wall Street analyst 12-month amount mark is $31.50. At the most recent market close, shares of Syndax Pharmaceuticals Inc. [NASDAQ:SNDX] were valued at $24.80. According to the average price forecast, investors can expect a potential return of 18.0%.
Syndax Pharmaceuticals Inc. [NASDAQ:SNDX] most recently reported quarterly sales of 379.0 million, which represented growth of 0.00%. This publicly-traded organization’s revenue is $43,343 per employee, while its income is -$1,601,343 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -76.02, -132.43, -134.52 and -131.77 respectively.
The Principal structure of this organization shows its whole liability to whole principal at 2.76 and the whole liability to whole assets at 1.41. It shows enduring liability to the whole principal at 1.29 and enduring liability to assets at 0.01 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 23.45 points at 1st support level, the second support level is making up to 22.33. But as of 1st resistance point, this stock is sitting at 25.29 and at 26.01 for 2nd resistance point.
Syndax Pharmaceuticals Inc. [SNDX] reported its earnings at -$0.46 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.44/share signifying the difference of -0.02 and -4.50% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.42 calling estimates for -$0.45/share with the difference of 0.03 depicting the surprise of 6.70%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Syndax Pharmaceuticals Inc. [NASDAQ:SNDX] is 11.70. Likewise, the Quick ratio is also the same, showing Cash ratio at 3.25. Now if looking for a valuation of this stock’s amount to sales ratio it’s 176.47 and it’s amount to book ratio is 7.54.
The most recent insider trade was by Metzger Michael A, President and COO, and it was the sale of 15000.0 shares on Dec 01. Ordentlich Peter, the Chief Scientific Officer, completed a sale of 29972.0 shares on Nov 23. On Nov 10, Morrison Briggs, Chief Executive Officer, completed a sale of 17466.0 shares.